Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial.

@article{Smith2013AntidepressantAU,
  title={Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial.},
  author={Eric Smith and Kristina M Deligiannidis and Christine M Ulbricht and Chelsea S Landolin and Jayendra K Patel and Anthony J Rothschild},
  journal={The Journal of clinical psychiatry},
  year={2013},
  volume={74 10},
  pages={966-73}
}
OBJECTIVE Intravenous N-methyl-d-aspartate (NMDA) antagonists have shown promising results in rapidly ameliorating depression symptoms, but placebo-controlled trials of oral NMDA antagonists as monotherapy have not observed efficacy. We conducted a randomized, double-blind, placebo-controlled trial of the NMDA antagonist memantine as an augmentation treatment for patients with DSM-IV major depressive disorder. METHOD Adult outpatients with major depressive disorder and partial response or… CONTINUE READING